Table 1.

Cumulative VE by infant month of age as a function of maternal RSV A/B-neutralizing titer GMFRs, based on a model of real-world observations.

	RSV A/B-Neutralizing Titer (GMFR) a
Infant Age (Month)	2x	3x	4x	5x	6x	7x	8x	10x	12x	16x	20x	24x	28x
0–1	0.32	0.53	0.65	0.72	0.78	0.82	0.85	0.89	0.91	0.94	0.96	0.97	0.98
0–2	0.28	0.47	0.60	0.67	0.73	0.77	0.8	0.85	0.88	0.92	0.94	0.96	0.97
0–3	0.24	0.43	0.55	0.62	0.68	0.73	0.76	0.81	0.85	0.89	0.92	0.94	0.95
0–4	0.22	0.40	0.51	0.59	0.65	0.69	0.73	0.79	0.82	0.87	0.90	0.92	0.94
0–5	0.21	0.38	0.49	0.56	0.62	0.67	0.70	0.76	0.80	0.85	0.89	0.91	0.92
0–6	0.20	0.36	0.47	0.54	0.60	0.64	0.68	0.73	0.77	0.83	0.87	0.89	0.91

Abbreviations: GMFR = geometric mean fold rise; VE = vaccine efficacy. ^a Cumulative VE was modeled using immunogenicity data reported from the RSVpreF first-in-human phase 1/2 study [27].